Co-Authors
This is a "connection" page, showing publications co-authored by Sarah Leist and Alexandra Schäfer.
Connection Strength
1.768
-
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med. 2021 03 01; 218(3).
Score: 0.233
-
A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell. 2020 11 12; 183(4):1070-1085.e12.
Score: 0.226
-
Cell and animal models of SARS-CoV-2 pathogenesis and immunity. Dis Model Mech. 2020 09 01; 13(9).
Score: 0.225
-
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Rep. 2021 07 27; 36(4):109450.
Score: 0.060
-
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity. 2021 08 10; 54(8):1869-1882.e6.
Score: 0.060
-
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science. 2021 08 27; 373(6558):991-998.
Score: 0.060
-
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021 03; 591(7850):451-457.
Score: 0.058
-
Publisher Correction: A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2021 Feb; 590(7844):E22.
Score: 0.058
-
Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. PLoS Pathog. 2021 01; 17(1):e1009287.
Score: 0.058
-
Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight. 2021 01 11; 6(1).
Score: 0.058
-
A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines (Basel). 2020 Dec 17; 8(4).
Score: 0.057
-
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine. 2020 Dec; 62:103132.
Score: 0.057
-
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020 12 18; 370(6523):1464-1468.
Score: 0.057
-
Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2020 11 24; 117(47):29832-29838.
Score: 0.057
-
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell. 2020 11 25; 183(5):1367-1382.e17.
Score: 0.057
-
High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. Cell. 2020 10 15; 183(2):429-441.e16.
Score: 0.056
-
A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020 10; 586(7830):560-566.
Score: 0.056
-
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020 10; 586(7830):567-571.
Score: 0.056
-
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020 07 21; 32(3):107940.
Score: 0.056
-
SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. 2020 07 23; 182(2):429-446.e14.
Score: 0.055
-
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 04 29; 12(541).
Score: 0.055
-
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 01 10; 11(1):222.
Score: 0.054